Procept BioRobotics Securities Fraud Class Action
Analysis based on 6 articles · First reported Aug 03, 2026 · Last updated Sep 01, 2026
The allegations and subsequent disclosures have eroded investor confidence in PROCEPT BioRobotics, leading to significant stock price declines of 16%, 10%, and 18% following each earnings announcement. The class action lawsuit adds legal and financial uncertainty, potentially impacting the company's valuation and future sales prospects.
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) and certain current and former executive officers, alleging violations of the Securities Exchange Act of 1934. The complaint, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.), claims that during the Class Period (February 28, 2024 to February 25, 2026), Procept used an undisclosed discount program to incentivize customers to place bulk orders exceeding actual procedure demand. This allegedly inflated reported U.S. handpiece unit sales and revenues by pulling forward future sales, creating a glut of field inventory of more than 10,000 excess units by the end of the Class Period. The lawsuit further alleges that Procept's 2025 handpiece sales and revenue guidance lacked a reasonable factual basis. The stock price fell significantly following quarterly earnings disclosures in August 2025, November 2025, and February 2026, which revealed declining handpiece sales and inventory issues. Robbins Geller Rudman & Dowd LLP LLP represents the lead plaintiff and has announced a September 22, 2026 deadline for investors to seek appointment as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard